TrialLancet (London, England)2023

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.

Arvind Dasari et al.PubMed ↗Publisher ↗

No numbers read from the abstract.